Contract Pharma Staff10.02.20
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired Alcami’s Germantown, WI, facility in the U.S.
The new facility will further bolster Sterling’s U.S. presence and will provide additional capacity for customer API development and manufacturing projects, specifically those with complex and hazardous requirements. The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities. Germantown has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.
The acquisition follows Sterling’s sustained growth over the past four years, which has seen the company invest $46 million into its service offering. This is including a recent $1.5 million investment into the company’s Cary facility in the U.S.
“We’re delighted to announce our acquisition of the Germantown facility in the U.S.,” said Kevin Cook, chief executive officer, Sterling Pharma Solutions. “This is the latest step of our strategic growth plans. It will ensure we continue to provide a strong transatlantic API presence to support our customers.
“The U.S. market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing, the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to the organization. We’re excited to welcome the Germantown team into the Sterling family.”
Walt Kaczmarek, chief executive officer, Alcami, said, “Our Germantown campus has been a high-performing site for Alcami. We want to thank the leadership team and employees for their dedication to the business. Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”
This announcement follows several expansion projects, including Alcami’s build of the sterile manufacturing site in Charleston, SC and the TriPharm acquisition completed in January 2020. Alcami is adding substantial sterile manufacturing and laboratory capacity with the best-in-class facility and equipment design.
The new facility will further bolster Sterling’s U.S. presence and will provide additional capacity for customer API development and manufacturing projects, specifically those with complex and hazardous requirements. The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities. Germantown has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.
The acquisition follows Sterling’s sustained growth over the past four years, which has seen the company invest $46 million into its service offering. This is including a recent $1.5 million investment into the company’s Cary facility in the U.S.
“We’re delighted to announce our acquisition of the Germantown facility in the U.S.,” said Kevin Cook, chief executive officer, Sterling Pharma Solutions. “This is the latest step of our strategic growth plans. It will ensure we continue to provide a strong transatlantic API presence to support our customers.
“The U.S. market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing, the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to the organization. We’re excited to welcome the Germantown team into the Sterling family.”
Walt Kaczmarek, chief executive officer, Alcami, said, “Our Germantown campus has been a high-performing site for Alcami. We want to thank the leadership team and employees for their dedication to the business. Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”
This announcement follows several expansion projects, including Alcami’s build of the sterile manufacturing site in Charleston, SC and the TriPharm acquisition completed in January 2020. Alcami is adding substantial sterile manufacturing and laboratory capacity with the best-in-class facility and equipment design.
